首页> 外文期刊>The lancet oncology >Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oesophageal cancer: A multicentre, randomised phase 3 trial
【24h】

Conventional stents versus stents loaded with 125iodine seeds for the treatment of unresectable oesophageal cancer: A multicentre, randomised phase 3 trial

机译:常规支架与装有125碘种子的支架用于治疗无法切除的食道癌:一项多中心,随机,3期试验

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The combination of stent insertion and single high-dose brachytherapy is a feasible and safe palliative treatment regimen in patients with unresectable oesophageal cancer. We aimed to further assess the efficacy of this treatment strategy compared to a conventional covered stent in patients with dysphagia caused by unresectable oesophageal cancer. Methods: In this multicentre, single-blind, randomised, phase 3 trial, we enrolled patients with unresectable oesophageal cancer from 16 hospitals in China. We included adult patients (aged ≥20 years) with progressive dysphagia, unresectable tumours due to extensive lesions, metastases, or poor medical condition, and with clear consciousness, cooperation, and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3. Eligible patients were randomly assigned (in 1:1 ratio, no stratification) to receive either a stent loaded with 125iodine radioactive seeds (irradiation group) or a conventional oesophageal stent (control group). The primary endpoint was overall survival. Survival analyses were done in a modified intention-to-treat group. This study is registered with ClinicalTrials.gov, number NCT01054274. Findings: Between Nov 1, 2009, and Oct 31, 2012, 160 patients were randomly assigned to receive treatment with either an irradiation stent (n=80) or a conventional stent (n=80). During a median follow-up of 138 days (IQR 72-207), 148 stents (73 in the irradiation group and 75 in the control group) were successfully placed into the diseased oesophagus in 148 participants. Median overall survival was 177 days (95% CI 153-201) in the irradiation group versus 147 days (124-170) in the control group (p=0·0046). Major complications and side-effects of the treatment were severe chest pain (17 [23%] of 73 patients in the irradiation group vs 15 [20%] of 75 patents in the control group), fistula formation (six [8%] vs five [7%]), aspiration pneumonia (11 [15%] vs 14 [19%]), haemorrhage (five [7%] vs five [7%]), and recurrent dysphagia (21 [28%] vs 20 [27%]). Interpretation: In patients with unresectable oesophageal cancer, the insertion of an oesophageal stent loaded with 125iodine seeds prolonged survival when compared with the insertion of a conventional covered self-expandable metallic stent. Funding: National High-tech Research Foundation of China, National Basic Research Program of China, Jiangsu Provincial Special Program of Medical Science, National Scientific and Technical Achievement Translation Foundation, and National Natural Science Foundation of China.
机译:背景:对于无法切除的食管癌患者,将支架置入和单次大剂量近距离放射治疗相结合是一种可行且安全的姑息治疗方案。我们旨在与传统的覆膜支架相比,在无法切除的食管癌引起的吞咽困难的患者中进一步评估该治疗策略的疗效。方法:在这项多中心,单盲,随机,3期试验中,我们纳入了中国16家医院的不可切除食管癌患者。我们纳入了患有进行性吞咽困难,由于广泛的病变,转移或医疗状况差,无法清除的肿瘤,意识清晰,合作且东部合作肿瘤小组(ECOG)表现状态评分为0-的成年患者(≥20岁) 3。符合条件的患者被随机分配(比例为1:1,无分层)以接受装有125碘放射性种子的支架(辐照组)或常规食道支架(对照组)。主要终点是总体生存率。在改良的意向治疗组中进行生存分析。该研究已在ClinicalTrials.gov上注册,编号为NCT01054274。结果:在2009年11月1日至2012年10月31日之间,随机分配了160名患者接受放射支架(n = 80)或常规支架(n = 80)的治疗。在138天的中位随访期间(IQR 72-207),将148个支架(辐照组中的73个,对照组中的75个)成功地放入了148名参与者的患病食道中。辐照组中位总生存期为177天(95%CI 153-201),而对照组为147天(124-170)(p = 0·0046)。治疗的主要并发症和副作用是严重的胸痛(放疗组73例患者中17例[23%],对照组75例中15例[20%]),瘘管形成(6例[8%] 5 [7%]),吸入性肺炎(11 [15%] vs 14 [19%]),出血(5 [7%] vs 5 [7%])和反复性吞咽困难(21 [28%] vs 20 [ 27%])。解释:在无法切除的食道癌患者中,与传统的有盖自扩张金属支架相比,插入装有125碘种子的食道支架可以延长生存期。资助项目:国家高技术研究基金会,国家基础研究计划,江苏省医学专项计划,国家科学技术成果转化基金会和国家自然科学基金。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号